Wall Street brokerages forecast that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will announce sales of $830,000.00 for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Oramed Pharmaceuticals’ earnings. The highest sales estimate is $1.18 million and the lowest is $600,000.00. Oramed Pharmaceuticals reported sales of $620,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 33.9%. The company is scheduled to report its next quarterly earnings results on Wednesday, November 27th.
On average, analysts expect that Oramed Pharmaceuticals will report full-year sales of $2.86 million for the current financial year, with estimates ranging from $2.50 million to $3.37 million. For the next year, analysts anticipate that the firm will post sales of $2.60 million, with estimates ranging from $2.40 million to $2.80 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Oramed Pharmaceuticals.
Oramed Pharmaceuticals (NASDAQ:ORMP) last released its quarterly earnings results on Wednesday, July 10th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.23). Oramed Pharmaceuticals had a negative net margin of 568.43% and a negative return on equity of 56.15%. The business had revenue of $0.68 million for the quarter, compared to analyst estimates of $0.71 million.
NASDAQ ORMP traded down $0.13 on Thursday, hitting $3.21. The stock had a trading volume of 40,400 shares, compared to its average volume of 51,442. The business’s fifty day moving average price is $3.51 and its 200 day moving average price is $3.44. Oramed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $5.32. The stock has a market cap of $56.14 million, a price-to-earnings ratio of -3.73 and a beta of 1.34.
In other news, Director Leonard Sank purchased 20,000 shares of the business’s stock in a transaction on Tuesday, July 16th. The shares were acquired at an average cost of $3.47 per share, with a total value of $69,400.00. Following the completion of the acquisition, the director now owns 315,482 shares of the company’s stock, valued at $1,094,722.54. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders acquired 25,817 shares of company stock worth $91,009 over the last ninety days. Corporate insiders own 20.50% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC grew its holdings in shares of Oramed Pharmaceuticals by 50.5% during the second quarter. Renaissance Technologies LLC now owns 158,098 shares of the biotechnology company’s stock valued at $568,000 after buying an additional 53,043 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Oramed Pharmaceuticals by 137.2% during the fourth quarter. BlackRock Inc. now owns 69,343 shares of the biotechnology company’s stock valued at $208,000 after buying an additional 40,114 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Oramed Pharmaceuticals during the second quarter valued at $155,000. 6.15% of the stock is currently owned by hedge funds and other institutional investors.
Oramed Pharmaceuticals Company Profile
Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.
Featured Story: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.